PROTEUS Trial

Design - Phase 3 perioperative apalutamide + ADT vs placebo + ADT around radical prostatectomy, high-risk localized/locally advanced prostate cancer, n=2,109 (NCT03767244); ASCO 2026 Plenary.

pCR/MRD (co-primary) - 8.9% vs 1.0%, OR 10.17 (95% CI 5.27-19.64), P<0.0001 - MET.

MFS (co-primary) - HR 0.80 (95% CI 0.67-0.96), P=0.02; 5-year MFS 78.2% vs 73.5% - MET. Distant metastasis HR 0.68 (95% CI 0.55-0.83), P=0.0002.

OS - Exploratory, not powered - HR 1.08, no benefit.

Safety - Grade 3/4 AEs 39.6% vs 31.0%, driven by rash (21.2% vs 10.0%), a known apalutamide class effect.

Regulatory - Investigational in perioperative localized disease; apalutamide is FDA approved in nmCRPC and mCSPC.

Sponsor / drug - Johnson & Johnson / Janssen; apalutamide (Erleada).

Compiled and reviewed by the KOL Pulse research team, led by Brian Shields, Founder, KOL Pulse. Last updated July 21, 2026.

Pathologic Complete Response / MRD (Co-Primary Endpoint)

PROTEUS met the pCR/MRD co-primary endpoint. The pCR/MRD rate was 8.9% with apalutamide + ADT versus 1.0% with placebo + ADT — odds ratio 10.17 (95% CI 5.27–19.64), p<0.0001, a roughly nine-fold improvement after six cycles of neoadjuvant therapy. The stricter ypT0 (no residual tumor) rate was 5.1% vs 0.4%. Positive surgical margins at prostatectomy were present in 20.9% vs 42.7%, and an exploratory residual cancer burden response was reported in 30.6% vs 11.7% (OR 3.36, 95% CI 2.67–4.23, p<0.0001).

Metastasis-Free Survival (Co-Primary Endpoint)

PROTEUS also met the MFS co-primary endpoint. By blinded independent central review, apalutamide + ADT produced a statistically significant 20% reduction in the risk of metastasis or death — HR 0.80 (95% CI 0.67–0.96), p=0.02, with five-year MFS rates of 78.2% vs 73.5%. Investigator-assessed MFS was directionally stronger (HR 0.74, 95% CI 0.62–0.87, p=0.0004). MFS was defined by conventional or PSMA-PET imaging. By conventional imaging alone, the difference was not statistically significant (HR 0.84, 95% CI 0.67–1.07); the significant primary result was driven substantially by PSMA-PET detection of distant metastases.

Distant Metastasis & Recurrence (Secondary)

Time to distant metastasis (by conventional or PSMA-PET) favored apalutamide: HR 0.68 (95% CI 0.55–0.83), p=0.0002, with five-year distant-metastasis-free rates of 82.8% vs 76.2%. Investigators also reported a 29% reduction in prostate cancer recurrence (event-free survival HR 0.71, 95% CI 0.63–0.80, p<0.0001; median EFS 57.1 vs 38.4 months). Median time to first subsequent therapy was 74.2 vs 41.5 months (HR 0.65, 95% CI 0.57–0.73, p<0.0001). Fewer apalutamide patients required subsequent therapy of any kind (42.4% vs 56.7%), including less subsequent systemic therapy (26.7% vs 36.4%) and less postoperative radiotherapy (13.0% vs 18.4%).

Overall Survival (Exploratory — No Benefit)

Overall survival was an exploratory measure and the trial was not powered to detect it. At a median follow-up of five years with overall mortality of 8.5%, the hazard ratio for death was 1.08 — numerically unfavorable, though below the prespecified threshold for unacceptable detriment, and not a demonstration of survival benefit. The accompanying NEJM editorial stated that a confirmed OS benefit with longer follow-up has not been shown.

Safety & Tolerability

Grade 3 or 4 adverse events occurred in 39.6% of the apalutamide arm versus 31.0% of the placebo arm, with the difference driven primarily by rash (21.2% vs 10.0%) — a well-characterized apalutamide class effect. The overall profile was consistent with prior apalutamide experience (SPARTAN, TITAN), and no new safety signals were reported in the perioperative setting.

Regulatory & Clinical Implications

Apalutamide (Erleada) is currently FDA-approved in non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic castration-sensitive prostate cancer (mCSPC). PROTEUS provides the first Phase 3 evidence for perioperative apalutamide in localized/locally advanced disease — an investigational use. Johnson & Johnson has positioned the dual-primary win as supporting a paradigm shift toward systemic-plus-surgery intensification. The trial met both co-primary endpoints (pCR/MRD and MFS); overall survival was exploratory with HR 1.08 and is not yet a demonstration of benefit.

What is the PROTEUS trial?

PROTEUS is a Phase 3 randomized, double-blind trial (NCT03767244; n=2,109) of perioperative apalutamide (Erleada) plus androgen deprivation therapy (ADT) versus placebo plus ADT, given before and after radical prostatectomy, in newly diagnosed high-risk localized or locally advanced prostate cancer. Pathologic complete response/minimal residual disease and metastasis-free survival were dual primary endpoints. It was presented as an ASCO 2026 Plenary.

What did PROTEUS show for its dual primary endpoints?

PROTEUS met both co-primary endpoints. The pathologic complete response/MRD rate was 8.9% with apalutamide plus ADT versus 1.0% with placebo plus ADT (odds ratio 10.17; 95% CI 5.27-19.64; P<0.0001), and metastasis-free survival improved with a hazard ratio of 0.80 (95% CI 0.67-0.96; P=0.02), a 5-year MFS of 78.2% versus 73.5%. Time to distant metastasis also favored apalutamide (HR 0.68; 95% CI 0.55-0.83; P=0.0002).

Did PROTEUS improve overall survival?

No. Overall survival was an exploratory, non-powered endpoint and showed no benefit (hazard ratio 1.08). The positive results were driven by the pathologic response and metastasis-free survival endpoints, not by an overall survival advantage.

Is perioperative apalutamide FDA approved for localized prostate cancer?

No. Perioperative apalutamide (Erleada) plus ADT for high-risk localized or locally advanced prostate cancer, as studied in PROTEUS, is investigational and not FDA approved. Apalutamide is FDA approved for non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic castration-sensitive prostate cancer (mCSPC); PROTEUS provides the first Phase 3 evidence in the perioperative localized setting, pending regulatory review.

What is the safety profile in PROTEUS?

Grade 3 or 4 adverse events occurred in 39.6% of the apalutamide arm versus 31.0% of the placebo arm, with the difference driven mainly by rash (21.2% vs 10.0%), a well-characterized apalutamide class effect. The overall profile was consistent with the known apalutamide plus ADT safety experience.